A comparative analysis for anti-viral drugs : Their efficiency against SARS-CoV-2
Copyright © 2020 Elsevier B.V. All rights reserved..
Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2021 |
|---|
| Contained In: |
International immunopharmacology - Vol. 90 (2021), p. 107232 |
|---|
| Language: |
English |
|---|
| Contributors: |
|---|
| Links: |
|---|
| Keywords: |
*SARS-CoV-2 |
|---|
| Notes: |
Date Completed 22.01.2021 Date Revised 27.01.2021 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1016/j.intimp.2020.107232 |
|---|---|
| PMID: |
33290969 |
| PPN (Catalogue-ID): |
NLM319570738 |
|---|
| LEADER | 03508nma a2200697 c 4500 | ||
|---|---|---|---|
| 001 | NLM319570738 | ||
| 003 | DE-601 | ||
| 005 | 20210127213918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201209s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1016/j.intimp.2020.107232 |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1125.xml |
| 035 | |a S1567-5769(20)33699-7 | ||
| 035 | |a (DE-599)NLM33290969 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Kivrak, Arif | |
| 245 | 1 | 2 | |a A comparative analysis for anti-viral drugs |h Elektronische Ressource |b Their efficiency against SARS-CoV-2 |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 22.01.2021 | ||
| 500 | |a Date Revised 27.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Coronavirus, known as the coronavirus pandemic, is continuing its spread across the world, with over 42 million confirmed cases in 189 countries and more than 1.15 million deaths. Although, scientists focus on the finding novel drugs and vaccine for SARS-CoV-2, there is no certain treatment for it. Antiviral drugs such as; oseltamivir, favipiravir, umifenovir, lopinavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ascorbic acid, corticosteroids, are mostly used for patients. They prevent cytokine storm that is the main reason of deaths related to SARS-CoV-2. In addition, anti-inflammatory agents have critical roles to inhibit the lung injury and multisystem organ dysfunction. The combination with anti-viral drugs with other drugs displays high synergistic effects. In the present study, the drugs used for Covid-19 are analyzed and compare the efficiency for the Covid-19 patients from the different continents including USA, South Korea, Italy, Spain, Germany, Russia, Brazil, Turkey, and China. Nowadays, all countries tried to find vaccine and new drug candidates for SARS-CoV-2, but anti-viral drugs may be the best candidates for the treatment of Covid-19 before finding novel anti-Covid drug | ||
| 611 | 2 | 7 | |a Comparative Study |2 gnd |
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 611 | 2 | 7 | |a Review |2 gnd |
| 653 | 2 | |a Antiviral Agents |6 D000998 |a chemistry |6 Q000737 |a *therapeutic use |6 Q000627 | |
| 653 | 2 | |a COVID-19 |6 D000086382 |a diagnosis |6 Q000175 |a *drug therapy |6 Q000188 |a epidemiology |6 Q000453 |a prevention & control |6 Q000517 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a *SARS-CoV-2 |6 D000086402 | |
| 653 | 2 | |a Treatment Outcome |6 D016896 | |
| 655 | 7 | |a Anti-viral |2 gnd | |
| 655 | 7 | |a Covid-19 |2 gnd | |
| 655 | 7 | |a Drug |2 gnd | |
| 655 | 7 | |a Favipiravir |2 gnd | |
| 655 | 7 | |a Remdesevir |2 gnd | |
| 655 | 7 | |a SARS-CoV-2 |2 gnd | |
| 655 | 7 | |a Antiviral Agents |2 gnd | |
| 689 | 0 | 0 | |A f |a Comparative Study |
| 689 | 0 | 1 | |A f |a Journal Article |
| 689 | 0 | 2 | |A f |a Review |
| 689 | 0 | |5 DE-601 | |
| 689 | 1 | 0 | |a Anti-viral |
| 689 | 1 | 1 | |a Covid-19 |
| 689 | 1 | 2 | |a Drug |
| 689 | 1 | 3 | |a Favipiravir |
| 689 | 1 | 4 | |a Remdesevir |
| 689 | 1 | 5 | |a SARS-CoV-2 |
| 689 | 1 | |5 DE-601 | |
| 689 | 2 | 0 | |a Antiviral Agents |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Ulaş, Berdan | |
| 700 | 1 | |a Kivrak, Hilal | |
| 773 | 0 | 8 | |i in |t International immunopharmacology |g Vol. 90 (2021), p. 107232 |q 90<107232 |w (DE-601)NLM112642683 |x 1878-1705 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.intimp.2020.107232 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2021 |b 05 |c 01 |h 107232 | ||